Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms- |
Target |
Action degraders, inhibitors |
Mechanism SMARCA2 degraders(Probable global transcription activator SNF2L2 degraders), SMARCA4 inhibitors(Transcription activator BRG1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Marginal Zone B-Cell Lymphoma | Preclinical | Switzerland | 27 Apr 2025 | |
Marginal Zone B-Cell Lymphoma | Preclinical | United States | 27 Apr 2025 | |
Marginal Zone B-Cell Lymphoma | Preclinical | Italy | 27 Apr 2025 |